
Javier Martinez-Picado

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4749189/publications.pdf Version: 2024-02-01



INVIED MADTINEZ-DICADO

#	Article	IF	CITATIONS
1	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,983
2	A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. Science, 2007, 317, 944-947.	6.0	1,136
3	HIV evolution: CTL escape mutation and reversion after transmission. Nature Medicine, 2004, 10, 282-289.	15.2	769
4	HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature Medicine, 2010, 16, 460-465.	15.2	500
5	Towards an HIV cure: a global scientific strategy. Nature Reviews Immunology, 2012, 12, 607-614.	10.6	485
6	HIV-1 remission following CCR5î"32/î"32 haematopoietic stem-cell transplantation. Nature, 2019, 568, 244-248.	13.7	447
7	Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1. Journal of Virology, 2006, 80, 3617-3623.	1.5	408
8	Common Genetic Variation and the Control of HIV-1 in Humans. PLoS Genetics, 2009, 5, e1000791.	1.5	377
9	Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1. Journal of Virology, 1999, 73, 3744-3752.	1.5	373
10	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	5.6	357
11	Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet, The, 2013, 381, 2109-2117.	6.3	275
12	Immune Selection for Altered Antigen Processing Leads to Cytotoxic T Lymphocyte Escape in Chronic HIV-1 Infection. Journal of Experimental Medicine, 2004, 199, 905-915.	4.2	266
13	Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells. Journal of Virology, 2014, 88, 10056-10065.	1.5	242
14	Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature, 2021, 598, 342-347.	13.7	230
15	Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature, 2022, 603, 587-598.	13.7	216
16	Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood, 2009, 113, 2732-2741.	0.6	208
17	Siglec-1 Is a Novel Dendritic Cell Receptor That Mediates HIV-1 Trans-Infection Through Recognition of Viral Membrane Gangliosides. PLoS Biology, 2012, 10, e1001448.	2.6	208
18	Antiretroviral resistance during successful therapy of HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10948-10953.	3.3	205

#	Article	IF	CITATIONS
19	Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. Aids, 2000, 14, 2857-2867.	1.0	194
20	A Dendritic Cell–Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. Science Translational Medicine, 2013, 5, 166ra2.	5.8	193
21	Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. Aids, 2000, 14, 397-403.	1.0	189
22	HIV and Mature Dendritic Cells: Trojan Exosomes Riding the Trojan Horse?. PLoS Pathogens, 2010, 6, e1000740.	2.1	184
23	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. Journal of Clinical Investigation, 2011, 121, 2391-2400.	3.9	168
24	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14658-14663.	3.3	154
25	Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV,the, 2020, 7, e340-e347.	2.1	151
26	Definition of the viral targets of protective HIV-1-specific T cell responses. Journal of Translational Medicine, 2011, 9, 208.	1.8	143
27	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. Lancet HIV,the, 2019, 6, e259-e268.	2.1	139
28	HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. Aids, 2001, 15, F19-F27.	1.0	135
29	Persistent HIV-1 replication during antiretroviral therapy. Current Opinion in HIV and AIDS, 2016, 11, 417-423.	1.5	133
30	Copy Number Variation of KIR Genes Influences HIV-1 Control. PLoS Biology, 2011, 9, e1001208.	2.6	132
31	Cell entry and export of nucleoside analogues. Virus Research, 2005, 107, 151-164.	1.1	127
32	A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. ELife, 2013, 2, e01123.	2.8	126
33	HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. Virus Research, 2008, 134, 104-123.	1.1	125
34	Transport of Lamivudine [(-)-β-l-2′,3′-Dideoxy-3′-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 252-261.	1.3	125
35	Efficacy of Lowâ€Dose Subcutaneous Interleukinâ€2 to Treat Advanced Human Immunodeficiency Virus Type 1 in Persons with ⩽250/μL CD4 T Cells and Undetectable Plasma Virus Load. Journal of Infectious Diseases, 1999, 180, 56-60.	1.9	110
36	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200413119.	3.3	110

#	Article	IF	CITATIONS
37	Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls. PLoS Pathogens, 2013, 9, e1003515.	2.1	109
38	Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study. Antiviral Therapy, 2012, 17, 355-364.	0.6	108
39	HIV-1 Capture and Transmission by Dendritic Cells: The Role of Viral Glycolipids and the Cellular Receptor Siglec-1. PLoS Pathogens, 2014, 10, e1004146.	2.1	108
40	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. Journal of Infectious Diseases, 2011, 203, 473-478.	1.9	105
41	CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Science Translational Medicine, 2018, 10, .	5.8	105
42	Maturation of Blood-Derived Dendritic Cells Enhances Human Immunodeficiency Virus Type 1 Capture and Transmission. Journal of Virology, 2007, 81, 7559-7570.	1.5	99
43	Infrequent Recovery of HIV from but Robust Exogenous Infection of Activated CD4 ⁺ T Cells in HIV Elite Controllers. Clinical Infectious Diseases, 2010, 51, 233-238.	2.9	98
44	Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral Therapy. Clinical Infectious Diseases, 2015, 61, 1169-1178.	2.9	97
45	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350.	15.2	96
46	Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. Aids, 2002, 16, 1009-1017.	1.0	92
47	Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. Aids, 2002, 16, 895-899.	1.0	85
48	HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells. Retrovirology, 2015, 12, 37.	0.9	85
49	Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. Journal of Experimental Medicine, 2006, 203, 529-539.	4.2	81
50	Sialyllactose in Viral Membrane Gangliosides Is a Novel Molecular Recognition Pattern for Mature Dendritic Cell Capture of HIV-1. PLoS Biology, 2012, 10, e1001315.	2.6	78
51	Dihydrosphingomyelin Impairs HIV-1 Infection by Rigidifying Liquid-Ordered Membrane Domains. Chemistry and Biology, 2010, 17, 766-775.	6.2	76
52	Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. Aids, 2007, 21, 169-178.	1.0	74
53	Exosomes and retroviruses: the chicken or the egg?. Cellular Microbiology, 2011, 13, 10-17.	1.1	71
54	HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics. PLoS ONE, 2012, 7, e40198.	1.1	71

#	Article	IF	CITATIONS
55	Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection. JAMA Oncology, 2020, 6, 1063.	3.4	70
56	Transcriptional Profiling of CD4 T Cells Identifies Distinct Subgroups of HIV-1 Elite Controllers. Journal of Virology, 2011, 85, 3015-3019.	1.5	69
57	Fitness of Human Immunodeficiency Virus Type 1 Protease Inhibitor-Selected Single Mutants. Virology, 2000, 275, 318-322.	1.1	68
58	Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. Journal of Antimicrobial Chemotherapy, 2015, 70, 3080-3086.	1.3	68
59	Role of Structured Treatment Interruption before a 5â€Drug Salvage Antiretroviral Regimen: The Retrogene Study. Journal of Infectious Diseases, 2003, 188, 977-985.	1.9	66
60	Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 558-567.	1.3	66
61	Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. Aids, 2018, 32, 2533-2545.	1.0	65
62	Drug uptake transporters in antiretroviral therapy. , 2011, 132, 268-279.		62
63	Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. Aids, 2014, 28, 325-334.	1.0	62
64	Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. Annals of Internal Medicine, 2018, 169, 674.	2.0	59
65	Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resourceâ€Limited Settings. Journal of Infectious Diseases, 2009, 200, 687-697.	1.9	56
66	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. Journal of Antimicrobial Chemotherapy, 2015, 70, 1833-1842.	1.3	56
67	Plasma-derived extracellular vesicles from Plasmodium vivax patients signal spleen fibroblasts via NF-kB facilitating parasite cytoadherence. Nature Communications, 2020, 11, 2761.	5.8	56
68	Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART. PLoS Pathogens, 2011, 7, e1002314.	2.1	55
69	Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. Aids, 2013, 27, 81-85.	1.0	55
70	Effect of an Electrolyte Additive of Vinylene Carbonate on the Electronic Structure at the Surface of a Lithium Cobalt Oxide Electrode under Battery Operating Conditions. Journal of Physical Chemistry C, 2015, 119, 9791-9797.	1.5	55
71	HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). Frontiers in Immunology, 2020, 11, 823.	2.2	55
72	Functional Consequences of Human Immunodeficiency Virus Escape from an HLA-B*13-Restricted CD8+ T-Cell Epitope in p1 Gag Protein. Journal of Virology, 2009, 83, 1018-1025.	1.5	54

#	Article	IF	CITATIONS
73	Resistance to Protease Inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26 Suppl 1, S34-S50.	0.9	53
74	Viral Dynamics during Structured Treatment Interruptions of Chronic Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2002, 76, 968-979.	1.5	52
75	CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report. Lancet HIV,the, 2015, 2, e236-e242.	2.1	52
76	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). EClinicalMedicine, 2019, 11, 65-80.	3.2	52
77	A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9981-9990.	3.3	51
78	Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation. Journal of Virology, 2016, 90, 6148-6158.	1.5	50
79	Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue. PLoS ONE, 2017, 12, e0175899.	1.1	50
80	Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure. Scientific Reports, 2020, 10, 1902.	1.6	50
81	Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. Journal of Virological Methods, 2006, 136, 102-117.	1.0	47
82	HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4. Retrovirology, 2008, 5, 32.	0.9	46
83	Contribution of Immunological and Virological Factors to Extremely Severe Primary HIV Type 1 Infection. Clinical Infectious Diseases, 2009, 48, 229-238.	2.9	44
84	Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. Aids, 2012, 26, 2285-2293.	1.0	44
85	Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry. Nature Microbiology, 2019, 4, 1558-1570.	5.9	44
86	A medium for presumptive identification of Vibrio anguillarum. Applied and Environmental Microbiology, 1994, 60, 1681-1683.	1.4	43
87	Alternation of Antiretroviral Drug Regimens for HIV Infection. Annals of Internal Medicine, 2003, 139, 81.	2.0	42
88	Capture of cell-derived microvesicles (exosomes and apoptotic bodies) by human plasmacytoid dendritic cells. Journal of Leukocyte Biology, 2012, 91, 751-758.	1.5	42
89	Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. Aids, 2006, 20, 2075-2080.	1.0	41
90	Modelling HIV-1 2-LTR dynamics following raltegravir intensification. Journal of the Royal Society Interface, 2013, 10, 20130186.	1.5	39

#	Article	IF	CITATIONS
91	Post COVID-19 Condition in Children and Adolescents: An Emerging Problem. Frontiers in Pediatrics, 2022, 10, .	0.9	39
92	Interaction of Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with the Concentrative Nucleoside Transporter-1 (Slc28A1). Antiviral Therapy, 2004, 9, 993-1002.	0.6	39
93	The infectious synapse formed between mature dendritic cells and CD4+T cells is independent of the presence of the HIV-1 envelope glycoprotein. Retrovirology, 2013, 10, 42.	0.9	38
94	A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. Human Molecular Genetics, 2013, 22, 1903-1910.	1.4	38
95	Mouse Siglec-1 Mediates trans-Infection of Surface-bound Murine Leukemia Virus in a Sialic Acid N-Acyl Side Chain-dependent Manner. Journal of Biological Chemistry, 2015, 290, 27345-27359.	1.6	38
96	Identification of Siglec-1 null individuals infected with HIV-1. Nature Communications, 2016, 7, 12412.	5.8	38
97	Human Immunodeficiency Virus Type 1 Cloning Vectors for Antiretroviral Resistance Testing. Journal of Clinical Microbiology, 1999, 37, 2943-2951.	1.8	38
98	A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. Journal of General Virology, 2003, 84, 2217-2228.	1.3	37
99	Fitness Variations and their Impact on the Evolution of Antiretroviral Drug Resistance. Current Drug Targets Infectious Disorders, 2003, 3, 355-371.	2.1	37
100	Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4 ⁺ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2016, 213, 1008-1012.	1.9	36
101	Evaluation of the immunogenicity and impact on the latent HIVâ€1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapyâ€treated subjects. Journal of the International AIDS Society, 2017, 20, 21171.	1.2	36
102	SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells. Cellular and Molecular Immunology, 2021, 18, 2676-2678.	4.8	36
103	Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology, 2004, 326, 103-112.	1.1	35
104	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Science Immunology, 2023, 8, .	5.6	35
105	Detailed Characterization of Early HIV-1 Replication Dynamics in Primary Human Macrophages. Viruses, 2018, 10, 620.	1.5	34
106	The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. Aids, 2010, 24, 17-25.	1.0	33
107	Dynamic Imaging of Cellâ€Free and Cellâ€Associated Viral Capture in Mature Dendritic Cells. Traffic, 2011, 12, 1702-1713.	1.3	32
108	Proteomics study of human cord blood reticulocyte-derived exosomes. Scientific Reports, 2018, 8, 14046.	1.6	32

#	Article	IF	CITATIONS
109	The PDZ-adaptor protein syntenin-1 regulates HIV-1 entry. Molecular Biology of the Cell, 2012, 23, 2253-2263.	0.9	31
110	Comparison of Sequencing by Hybridization and Cycle Sequencing for Genotyping of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Journal of Clinical Microbiology, 2000, 38, 2715-2721.	1.8	31
111	Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages. ELife, 2020, 9, .	2.8	31
112	Dendritic Cells From the Cervical Mucosa Capture and Transfer HIV-1 via Siglec-1. Frontiers in Immunology, 2019, 10, 825.	2.2	30
113	Mechanisms Involved in the Selection of HIV-1 Reverse Transcriptase Thumb Subdomain Polymorphisms Associated with Nucleoside Analogue Therapy Failure. Antimicrobial Agents and Chemotherapy, 2010, 54, 4799-4811.	1.4	29
114	Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence. Retrovirology, 2018, 15, 15.	0.9	29
115	Quantitative HIV-1 RNA as a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of 300×106/l. Aids, 1996, 10, F39-F44.	1.0	28
116	Prevalence of HIV Protease Mutations on Failure of Nelfinavir-Containing HAART: A Retrospective Analysis of Four Clinical Studies and Two Observational Cohorts. HIV Clinical Trials, 2002, 3, 316-323.	2.0	28
117	Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Research, 2010, 88, 281-286.	1.9	28
118	Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2013, 68, 2358-2362.	1.3	28
119	Actin-binding Protein Drebrin Regulates HIV-1-triggered Actin Polymerization and Viral Infection. Journal of Biological Chemistry, 2013, 288, 28382-28397.	1.6	28
120	Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals. PLoS ONE, 2014, 9, e114142.	1.1	27
121	Viral Evolution during Structured Treatment Interruptions in Chronically Human Immunodeficiency Virus-Infected Individuals. Journal of Virology, 2002, 76, 12344-12348.	1.5	26
122	Lack of Longitudinal Intrapatient Correlation between p24 Antigenemia and Levels of Human Immunodeficiency Virus (HIV) Type 1 RNA in Patients with Chronic HIV Infection during Structured Treatment Interruptions. Journal of Clinical Microbiology, 2004, 42, 1620-1625.	1.8	26
123	Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix. Vaccines, 2019, 7, 209.	2.1	25
124	When Dendritic Cells Go Viral: The Role of Siglec-1 in Host Defense and Dissemination of Enveloped Viruses. Viruses, 2020, 12, 8.	1.5	25
125	Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control. PLoS Pathogens, 2020, 16, e1008678.	2.1	25
126	HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. Journal of Infectious Diseases, 2016, 214, 1512-1519.	1.9	24

#	Article	IF	CITATIONS
127	Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Journal of Medical Virology, 2005, 77, 23-28.	2.5	23
128	Relative Fitness and Replication Capacity of a Multinucleoside Analogue-Resistant Clinical Human Immunodeficiency Virus Type 1 Isolate with a Deletion of Codon 69 in the Reverse Transcriptase Coding Region. Journal of Virology, 2007, 81, 4713-4721.	1.5	23
129	Impact of Phenotype Definition on Genome-Wide Association Signals: Empirical Evaluation in Human Immunodeficiency Virus Type 1 Infection. American Journal of Epidemiology, 2011, 173, 1336-1342.	1.6	23
130	Switching From a Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy–suppressed Human Immunodeficiency Virus–infected Individuals. Clinical Infectious Diseases, 2019, 69, 1320-1328.	2.9	23
131	HIGH-FREQUENCY failure of combination antiretroviral therapy in paediatric HIV infection is associated with unmet maternal needs causing maternal NON-ADHERENCE. EClinicalMedicine, 2020, 22, 100344.	3.2	23
132	HIV Type 1 Fitness Evolution in Antiretroviral-Experienced Patients with Sustained CD4+ T Cell Counts but Persistent Virologic Failure. Clinical Infectious Diseases, 2005, 41, 729-737.	2.9	22
133	Optimal Antiviral Switching to Minimize Resistance Risk in HIV Therapy. PLoS ONE, 2011, 6, e27047.	1.1	22
134	Cancer immunotherapy of patients with HIV infection. Clinical and Translational Oncology, 2019, 21, 713-720.	1.2	22
135	Raltegravir Susceptibility and Fitness Progression of HIV Type-1 Integrase in Patients on Long-Term Antiretroviral Therapy. Antiviral Therapy, 2008, 13, 881-893.	0.6	22
136	HIV-1 Capture and Antigen Presentation by Dendritic Cells: Enhanced Viral Capture Does Not Correlate with Better T Cell Activation. Journal of Immunology, 2012, 188, 6036-6045.	0.4	21
137	Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 152-160.	0.9	21
138	Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNAâ€methyltransferase inhibitors. British Journal of Pharmacology, 2014, 171, 3868-3880.	2.7	21
139	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. Aids, 2015, 29, 2323-2333.	1.0	21
140	Variability in the Plasma Concentration of Efavirenz and Nevirapine is Associated with Genotypic Resistance after Treatment Interruption. Antiviral Therapy, 2008, 13, 945-951.	0.6	21
141	Efficacy of Adding Indinavir to Previous Reverse Transcriptase Nucleoside Analogues in Relation to Genotypic and Phenotypic Resistance Development in Advanced HIV-1-Infected Patients. Journal of Acquired Immune Deficiency Syndromes, 1998, 19, 19-28.	0.3	20
142	Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab. Journal of Clinical Medicine, 2019, 8, 2089.	1.0	20
143	A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. Journal of Infectious Diseases, 2011, 204, 741-752.	1.9	19
144	Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. Journal of Antimicrobial Chemotherapy, 2018, 73, 1940-1948.	1.3	19

#	Article	IF	CITATIONS
145	Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report. Lancet Microbe, The, 2020, 1, e130-e135.	3.4	19
146	Gut microbiome signatures linked to HIV-1 reservoir size and viremia control. Microbiome, 2022, 10, 59.	4.9	19
147	Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC. Aids, 1996, 10, F61-F66.	1.0	18
148	Random T-Cell Receptor Recruitment in Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8 ⁺ T Cells from Genetically Identical Twins Infected with the Same HIV-1 Strain. Journal of Virology, 2007, 81, 12666-12669.	1.5	18
149	Mechanistic Basis of Zidovudine Hypersusceptibility and Lamivudine Resistance Conferred by the Deletion of Codon 69 in the HIV-1 Reverse Transcriptase Coding Region. Journal of Molecular Biology, 2008, 382, 327-341.	2.0	18
150	Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression. Aids, 2014, 28, 1261-1272.	1.0	18
151	Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch. HIV Medicine, 2015, 16, 388-392.	1.0	18
152	Identification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for <i>In Vivo</i> HIV Control. Journal of Virology, 2017, 91, .	1.5	18
153	Extremely low viral reservoir in treated chronically HIV-1-infected individuals. EBioMedicine, 2020, 57, 102830.	2.7	18
154	3′-Azido-2′,3′-Dideoxythymidine (Zidovudine) Uptake Mechanisms in T Lymphocytes. Antiviral Therapy, 2 11, 803-812.	006. 0.6	18
155	Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients. Aids, 2014, 28, 2157-2159.	1.0	17
156	Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells. Frontiers in Immunology, 2019, 9, 3162.	2.2	17
157	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. Science Translational Medicine, 2020, 12, .	5.8	17
158	P-glycoprotein (<i>ABCB1</i>) activity decreases raltegravir disposition in primary CD4+P-gp ^{high} cells and correlates with HIV-1 viral load. Journal of Antimicrobial Chemotherapy, 2016, 71, 2782-2792.	1.3	16
159	Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions. Frontiers in Pharmacology, 2016, 7, 175.	1.6	16
160	Influence of Prior Structured Treatment Interruptions on the Length of Time without Antiretroviral Treatment in Chronically HIV-Infected Subjects. AIDS Research and Human Retroviruses, 2004, 20, 1283-1288.	0.5	15
161	AM3 Modulates Dendritic Cell Pathogen Recognition Capabilities by Targeting DC-SIGN. Antimicrobial Agents and Chemotherapy, 2007, 51, 2313-2323.	1.4	15
162	Attacking the HIV Reservoir from the Immune and Viral Perspective. Current HIV/AIDS Reports, 2013, 10, 33-41.	1.1	15

#	Article	IF	CITATIONS
163	Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection. Nature Communications, 2020, 11, 1767.	5.8	15
164	Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals. PLoS ONE, 2014, 9, e87334.	1.1	15
165	Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Patients Who Are Chronically Infected with Human Immunodeficiency Virus Type 1. Journal of Virology, 2005, 79, 5907-5913.	1.5	14
166	Thymidine Analogue Excision and Discrimination Modulated by Mutational Complexes Including Single Amino Acid Deletions of Asp-67 or Thr-69 in HIV-1 Reverse Transcriptase. Journal of Biological Chemistry, 2011, 286, 20615-20624.	1.6	14
167	Lack of concordance between residual viremia and viral variants driving de novo infection of CD4+ T cells on ART. Retrovirology, 2016, 13, 51.	0.9	14
168	Retroviruses As Myeloid Cell Riders: What Natural Human Siglec-1 "Knockouts―Tell Us About Pathogenesis. Frontiers in Immunology, 2017, 8, 1593.	2.2	14
169	Differential Immunodominance Hierarchy of CD8 ⁺ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. Journal of Virology, 2018, 92, .	1.5	14
170	Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected Journal of Clinical Oncology, 2019, 37, 2501-2501.	0.8	14
171	In–Depth Characterization of Viral Isolates from Plasma and Cells Compared with Plasma Circulating Quasispecies in Early HIV-1 Infection. PLoS ONE, 2012, 7, e32714.	1.1	14
172	Assessing main death pathways in T lymphocytes from HIV infected individuals. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 648-658.	1.1	13
173	Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. Journal of Antimicrobial Chemotherapy, 2015, 70, 3087-3095.	1.3	13
174	Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors. Scientific Reports, 2017, 7, 3717.	1.6	13
175	Dasatinib protects humanized mice from acute HIV-1 infection. Biochemical Pharmacology, 2020, 174, 113625.	2.0	13
176	The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression. Clinical Infectious Diseases, 2021, 72, e256-e264.	2.9	13
177	Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. PLoS ONE, 2017, 12, e0184929.	1.1	13
178	Short Communication: Naive CD4+ T Cells and Recent Thymic Emigrant Levels in Treated Individuals with HIV: Clinical Relevance. AIDS Research and Human Retroviruses, 2006, 22, 893-896.	0.5	12
179	Effect of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Polymorphism Leu-214 on Replication Capacity and Drug Susceptibility. Journal of Virology, 2009, 83, 7434-7439.	1.5	12
180	Combined Antiretroviral Therapy and Immune Pressure Lead to In Vivo HIV-1 Recombination With Ancestral Viral Genomes. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 109-117.	0.9	12

#	Article	IF	CITATIONS
181	HIV-1 Tropism Testing in Subjects Achieving Undetectable HIV-1 RNA: Diagnostic Accuracy, Viral Evolution and Compartmentalization. PLoS ONE, 2013, 8, e67085.	1.1	12
182	Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. Scientific Reports, 2017, 7, 40800.	1.6	12
183	An HLA-I signature favouring KIR-educated Natural Killer cells mediates immune control of HIV in children and contrasts with the HLA-B-restricted CD8+ T-cell-mediated immune control in adults. PLoS Pathogens, 2021, 17, e1010090.	2.1	12
184	Improved CD4 Lymphocyte Outgrowth in Response to Effective Antiretroviral Therapy. Journal of Infectious Diseases, 1999, 179, 345-351.	1.9	11
185	Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus–related Lymphomas. Clinical Infectious Diseases, 2019, 68, 834-843.	2.9	11
186	Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). , 2021, 9, e001664.		11
187	Robust HIV-specific CD4+ and CD8+ T-cell responses distinguish elite control in adolescents living with HIV from viremic nonprogressors. Aids, 2022, 36, 95-105.	1.0	11
188	Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy. MBio, 2021, 12, e0307821.	1.8	11
189	Comparative Analysis of HIV Type 1 Genotypic Resistance across Antiretroviral Trial Treatment Regimens. AIDS Research and Human Retroviruses, 2000, 16, 1325-1336.	0.5	10
190	HIV integrase inhibitors in ART-experienced patients. Current Opinion in HIV and AIDS, 2012, 7, 415-421.	1.5	10
191	Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naive Adults Living With HIV–1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). Clinical Infectious Diseases, 2021, 73, e1991-e1999.	2.9	10
192	Evolution of HIV drug Resistance in Zidovudine/Zalcitabine- and Zidovudine/ Didanosine-Experienced Patients Receiving Lamivudine-Containing Combination Therapy. Antiviral Therapy, 1998, 3, 81-88.	0.6	10
193	Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. Vaccine, 2011, 29, 5711-5724.	1.7	9
194	Dissemination of <i>Mycobacterium tuberculosis</i> is associated to a <i>SIGLEC1</i> null variant that limits antigen exchange via trafficking extracellular vesicles. Journal of Extracellular Vesicles, 2021, 10, e12046.	5.5	9
195	Early Initiation of Antiretroviral Therapy Following In Utero HIV Infection Is Associated With Low Viral Reservoirs but Other Factors Determine Viral Rebound. Journal of Infectious Diseases, 2021, 224, 1925-1934.	1.9	9
196	VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies. MBio, 2021, 12, e0056021.	1.8	9
197	Alternation of Antiretroviral Drug Regimens for HIV Infection. Efficacy, Safety and Tolerability at Week 96 of the Swatch Study. Antiviral Therapy, 2004, 9, 889-893.	0.6	9
198	Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIVâ€lâ€infected patients with multidrugâ€resistant virus: a multicentre pilot study. HIV Medicine, 2008, 9, 508-513.	1.0	8

#	Article	IF	CITATIONS
199	Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. Biochemical Pharmacology, 2021, 192, 114666.	2.0	8
200	Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy. Antiviral Therapy, 2008, 13, 881-93.	0.6	8
201	The Status of the Alfalfa Snout Beetle in New York State1. Journal of Economic Entomology, 1971, 64, 1332-1333.	0.8	7
202	Transient Treatment Exclusively Containing Nucleoside Analogue Reverse Transcriptase Inhibitors in Highly Antiretroviral-Experienced Patients Preserves Viral Benefit When a Fully Active Therapy Was Initiated. HIV Clinical Trials, 2008, 9, 387-398.	2.0	7
203	A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors. Journal of Antimicrobial Chemotherapy, 2012, 67, 32-38.	1.3	7
204	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. Retrovirology, 2012, 9, 68.	0.9	7
205	Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses. Journal of Virology, 2018, 92, .	1.5	7
206	HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design. Journal of Antimicrobial Chemotherapy, 2020, 75, 2258-2263.	1.3	7
207	Motivations, barriers and experiences of participants in an HIV reservoir trial. Journal of Virus Eradication, 2021, 7, 100029.	0.3	7
208	ABX464 Decreases the Total Human Immunodeficiency Virus (HIV) Reservoir and HIV Transcription Initiation in CD4+ T Cells From Antiretroviral Therapy–Suppressed Individuals Living With HIV. Clinical Infectious Diseases, 2022, 74, 2044-2049.	2.9	7
209	Novel Two-Round Phenotypic Assay for Protease Inhibitor Susceptibility Testing of Recombinant and Primary HIV-1 Isolates. Journal of Clinical Microbiology, 2012, 50, 3909-3916.	1.8	6
210	Increasing Diagnostic Uncertainties in Children With In Utero HIV Infection. Pediatric Infectious Disease Journal, 2019, 38, e166-e168.	1.1	6
211	Altered Tâ€cell subset distribution in the viral reservoir in HIVâ€1â€infected individuals with extremely low proviral DNA (LoViReTs). Journal of Internal Medicine, 2022, 292, 308-320.	2.7	6
212	New Macrocyclic Amines Showing Activity as HIV Entry Inhibitors Against Wild Type and Multi-Drug Resistant Viruses. Molecules, 2009, 14, 1927-1937.	1.7	5
213	Relationship between CCR5(WTlî"32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection. Clinical Microbiology and Infection, 2017, 23, 318-324.	2.8	5
214	Response to "Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1― Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 343-345.	1.3	5
215	Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome. EBioMedicine, 2022, 78, 103956.	2.7	5
216	Risk of selecting resistance mutations during treatment interruption. Current Opinion in HIV and AIDS, 2007, 2, 6-13.	1.5	4

#	Article	IF	CITATIONS
217	Drug-Resistance Mutations Number and K70R or T215Y/F Substitutions Predict Treatment Resumption during Guided Treatment Interruptions. AIDS Research and Human Retroviruses, 2008, 24, 725-732.	0.5	4
218	The Magnitude of Interferon-Î ³ Responses to Human Cytomegalovirus Is Predictive for HIV-1 Disease Progression. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 507-512.	0.9	4
219	Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029. Clinical Microbiology and Infection, 2015, 21, 103.e1-103.e6.	2.8	4
220	Epstein–Barr viral loads and serum free light chains levels are potential follow-up markers of HIV-related lymphomas. Leukemia and Lymphoma, 2017, 58, 211-213.	0.6	4
221	Evidence for Preferential Genotyping of a Minority Human Immunodeficiency Virus Population Due to Primer-Template Mismatching during PCR-Based Amplification. Journal of Clinical Microbiology, 2005, 43, 436-438.	1.8	3
222	TL1A–DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1–Specific T Cell Responses. Journal of Immunology, 2020, 205, 3348-3357.	0.4	3
223	Transcriptional signature of resting-memory CD4 T cells differentiates spontaneous from treatment-induced HIV control. Journal of Molecular Medicine, 2020, 98, 1093-1105.	1.7	3
224	Communications: Iridovirus-like Particles Associated with Nodular Skin Lesions and Vesicles inParapocryptes serperaster. Journal of Aquatic Animal Health, 1993, 5, 148-151.	0.6	3
225	Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium. Journal of Virus Eradication, 2021, 7, 100045.	0.3	2
226	Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent. Journal of Antimicrobial Chemotherapy, 2021, 76, 1032-1040.	1.3	2
227	Past and future of HIV infection. A document based on expert opinion. Revista Espanola De Quimioterapia, 2022, 35, 131-156.	0.5	2
228	Long-term impact of antiretroviral strategies for a functional HIV cure: A virtual clinical trial. IFAC-PapersOnLine, 2018, 51, 80-85.	0.5	1
229	Safety of Anti–PD-L1 Inhibition in HIV-1–Infected Patients With Cancer—Reply. JAMA Oncology, 2020, 6, 1810.	3.4	1
230	Monocyte-derived DC Electroporated with mRNAs Encoding Both Specific HIV Antigens and DC Adjuvants Are Able to Improve T-cell Functionality. AIDS Research and Human Retroviruses, 2014, 30, A194-A194.	0.5	0
231	Siglec-1 Expressed on Dendritic Cells is a New Receptor Implicated in Arenavirus Uptake. Proceedings (mdpi), 2020, 50, 90.	0.2	0
232	Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors. Journal of Virology, 2022, 96, JVI0149921.	1.5	0
233	Next-generation point-of-care testing in pediatric human immunodeficiency virus infection facilitates diagnosis and monitoring of treatment. Medicine (United States), 2022, 101, e29228.	0.4	0